Histogenics, a biotech developing an implantable tissue repair platform for cartilage damage to the knee, filed on Tuesday with the SEC to raise up to $65 million in an initial public offering. The company's lead candidate, NeoCart, uses a patient's own...read more
Early Friday morning, Osiris Therapeutics, which is developing stem cell therapies for inflammatory, orthopedic and cardiovascular disorders, announced the completion of its 3.5 million share IPO. The deal priced at $11 per share, the low end of its proposed...read more
Osiris Therapeutics, a stem cell therapeutic company developing treatments for the inflammatory, orthopedic and cardiovascular areas, announced the terms for its IPO on Monday. The Baltimore based company plans to offer 3.5 millions shares at a range of $11-$13...read more
Osiris Therapeutics, a stem cell therapeutic company developing treatments for the inflammatory, orthopedic and cardiovascular areas, registered for an initial public offering Friday morning. Deutsche Bank is the sole underwriter listed on the deal. Terms and...read more
Need knee repair? Histogenics files for a $65 million IPO
Histogenics, a biotech developing an implantable tissue repair platform for cartilage damage to the knee, filed on Tuesday with the SEC to raise up to $65 million in an initial public offering. The company's lead candidate, NeoCart, uses a patient's own...read more
Osiris Therapeutics prices at low end of range
Early Friday morning, Osiris Therapeutics, which is developing stem cell therapies for inflammatory, orthopedic and cardiovascular disorders, announced the completion of its 3.5 million share IPO. The deal priced at $11 per share, the low end of its proposed...read more
Stem cell researcher Osiris Therapeutics announces terms for IPO
Osiris Therapeutics, a stem cell therapeutic company developing treatments for the inflammatory, orthopedic and cardiovascular areas, announced the terms for its IPO on Monday. The Baltimore based company plans to offer 3.5 millions shares at a range of $11-$13...read more
Stem cell researcher Osiris Therapeutics files for IPO
Osiris Therapeutics, a stem cell therapeutic company developing treatments for the inflammatory, orthopedic and cardiovascular areas, registered for an initial public offering Friday morning. Deutsche Bank is the sole underwriter listed on the deal. Terms and...read more